Media

Latest news

Press Releases

SEE ALL
May 10, 2024

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md. , May 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: BofA Securities Health Care Conference 2024 Fireside Chat: Wednesday, May 15, 2024 at 2:20 p.m.
May 08, 2024

REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights

Company remains on track for its first BLA filing in 2024 and is accelerating progress toward pivotal trial initiation for Duchenne (H2 2024) and diabetic retinopathy (H1 2025) Dose level 2 selected as pivotal dose for RGX-202 treatment of Duchenne New positive interim efficacy and safety data
May 01, 2024

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , May 1, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 8, 2024 , at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024 , and recent operational highlights.